Transforming growth factor-β1 (TGF-β1) levels in plasma of patients with prostate cancer and benign prostatic hyperplasia (BPH);Plasma-TGF-β1-konzentrationen bei patienten mit einem prostatakarzinom oder einer benignen prostatahyperplasie

Urologe - Ausgabe A

Volumn 37, Issue 2, 1998, Pages 199-202

  Lange, I ^a   Hammerer, P ^a   Knabbe, C ^a   Graefen, M ^a   Schmahl, M ^a   Huland, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Benign prostate hyperplasia; Growth factor; Prostate cancer; TGF 1

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ARTICLE; BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; BIOPSY; BLOOD; DIFFERENTIAL DIAGNOSIS; PATHOLOGY; PROSTATE; PROSTATE TUMOR;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 0032020574     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050174     Document Type: Article

References (15)

1. Dennis PA, Rifkin DB (1991) Cellular activation of latent transforming growth factor β requires binding to the cationindependent mannose 6-phosphate/insulin-like growth factor type 2 receptor. Proc Natl Acad Sci 88: 580-584
2. 2 in serum und urine from patients with bladder carcinoma. J Urol 156: 953-957
3. Hammerer P, Huland H (1994) Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Ural 151: 99
4. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J (1995) Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nature Med 4:282-284
5. Kojima S, Nara K, Rifkin DB (1993) Requirement for transglutaminase in the activation of latent transforming growth factor-β in bovine endothelial cells. J Cell Biol 121: 439-448
6. 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 55: 4512-4515
7. Laiho M, Keski-Oja J (1992) Transforming growth factors-β as regulators of cellular growth and phenotype. Crit Rev Oncogen 3: 1-26
8. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Oettersson K (1991) Prostate-specific antigen occurs at high concentration in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 64: 309
9. Miller DA, Pelton RW, Derynck R, Moses HL (1990) Transforming growth factor-β- a family of growth regulatory peptides. Ann N Y Acad Sci 593: 208-217
10. s. In: Sporn MB, Roberts AB (eds) Peptide growth factors and their receptors. Springer, Berlin Heidelberg New York, pp 419-472
11. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B (1987) Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 105:1039-1045
12. Steiner MS (1993) Role of peptide growth factors in the prostate: a review. Urology 42: 99-107
13. 1 - Overproduction in prostate cancer: effects on growth in vivo and in vito. Mol Endocrinol 6: 15-25
14. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER (1994) Expression of transforming growth factor-β1 in prostate cancer. Endocrinology 135: 2240-2247
15. Wakefield LM, Letterio JJ, Chen T, Danielpour D, Allison RSH, Pai LH, Denicoff AM, Noone MH, Cowan KH, O'Shaughnessy JA, Sporn MB (1995) Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 129: 129-136